Back

From trials to treatment: real-world vericiguat initiation and residual risk in Germany

29 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Acute heart failure therapies: timing, choices, and comparative effectiveness Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Fabian Kerwagen

University Hospital Wuerzburg, Wuerzburg (Germany)

5 More presentations in this session

Presentation thumbnail
SGLT2 inhibitor outcomes in elderly post-MI patients with mildly reduced ejection fraction: age-stratified real-world evidence
Doctor A. Ajibade (Iowa City, US)
Abstract
Presentation thumbnail
Impact of levosimendan versus dobutamine on 30-day mortality and hospital stay in acute decompensated heart failure: a systematic review and meta-analysis
Doctor H. Amorim Parente (Rio de Janeiro, BR)
Abstract
Presentation thumbnail
Early in-hospital initiation of dapagliflozin versus empagliflozin in acute heart failure: impact on in-hospital survival and safety
Doctor N. Benameur (Tangier, MA)
Abstract
Presentation thumbnail
Does initiating SGLT2 inhibitors at an early stage of heart failure admission really reduce cardiovascular mortality and first rehospitalization? A meta-analysis of randomized controlled trials
Doctor E. Alupei (RO)
Abstract
Presentation thumbnail
Early catheter ablation for atrial fibrillation in acute heart failure: prognostic impact across age and ejection fraction
Doctor A. Okahara (Fukuoka, JP)
Abstract

Access the full session

Session thumbnail
Acute heart failure therapies: timing, choices, and comparative effectiveness

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
27 August 2021
thumbnail
Congress Presentation
Heart-Failure related hospitalisations and cardiovascular events among patients with incident heart failure in Germany: a retrospective cohort study using AOK PLUS data - part of the HF-BoI Project
29 June 2021
thumbnail
Congress Presentation
Impact of worsening heart failure events and renal impairment on vericiguat drug use patterns in real-world care
19 May 2025
thumbnail
Congress Presentation
Real world data comparing HF guideline directed medical therapy before and after 2021 ESC HF guidelines.
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources